NUK - logo
E-resources
Full text
Peer reviewed Open access
  • Persistence of SARS-CoV-2 A...
    Hosseinian, Sina; Powers, Kathleen; Vasudev, Milind; Palma, Anton M; de Assis, Rafael; Jain, Aarti; Horvath, Peter; Birring, Paramveer S; Andary, Rana; Au, Connie; Chin, Brandon; Khalil, Ghali; Ventura, Jenny; Luu, Madeleine K; Figueroa, Cesar; Obiero, Joshua M; Silzel, Emily; Nakajima, Rie; Gombrich, William Thomas; Jasinskas, Algis; Zaldivar, Frank; Schubl, Sebastian; Felgner, Philip L; Khan, Saahir

    Frontiers in immunology, 04/2022, Volume: 13
    Journal Article

    Recent studies provide conflicting evidence on the persistence of SARS-CoV-2 immunity induced by mRNA vaccines. Here, we aim to quantify the persistence of humoral immunity following vaccination using a coronavirus antigen microarray that includes 10 SARS-CoV-2 antigens. In a prospective longitudinal cohort of 240 healthcare workers, composite SARS-CoV-2 IgG antibody levels did not wane significantly over a 6-month study period. In the subset of the study population previously exposed to SARS-CoV-2 based on seropositivity for nucleocapsid antibodies, higher composite anti-spike IgG levels were measured before the vaccine but no significant difference from unexposed individuals was observed at 6 months. Age, vaccine type, or worker role did not significantly impact composite IgG levels, although non-significant trends towards lower antibody levels in older participants and higher antibody levels with Moderna vaccine were observed at 6 months. A small subset of our cohort were classified as having waning antibody titers at 6 months, and these individuals were less likely to work in patient care roles and more likely to have prior exposure to SARS-CoV-2.